Compare Stocks: NNVC, AARD, ADCT, and HURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$6.60 +3.1%	$5.03	$3.35 ▼ $17.94	$140.06M	3.93	402,861 shs	89,271 shs
ADCT ADC Therapeutics	$1.05 -5.4%	$1.51	$0.78 ▼ $4.98	$141.18M	1.87	974,744 shs	757,704 shs
HURA TuHURA Biosciences	$2.17	$2.29	$0.41 ▼ $3.90	$138.19M	-0.05	286,743 shs	142,806 shs
NNVC NanoViricides	$1.52 -1.9%	$1.50	$0.85 ▼ $2.23	$35.62M	1.67	559,574 shs	132,941 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	+3.12%	+4.43%	+17.44%	+20.88%	-47.99%
ADCT ADC Therapeutics	-6.42%	-10.64%	-8.30%	-72.62%	-64.29%
HURA TuHURA Biosciences	-0.23%	+2.84%	-11.43%	-6.87%	-15.89%
NNVC NanoViricides	-1.94%	+2.70%	+12.59%	+16.92%	-9.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$6.60 +3.1%	$5.03	$3.35 ▼ $17.94	$140.06M	3.93	402,861 shs	89,271 shs
ADCT ADC Therapeutics	$1.05 -5.4%	$1.51	$0.78 ▼ $4.98	$141.18M	1.87	974,744 shs	757,704 shs
HURA TuHURA Biosciences	$2.17	$2.29	$0.41 ▼ $3.90	$138.19M	-0.05	286,743 shs	142,806 shs
NNVC NanoViricides	$1.52 -1.9%	$1.50	$0.85 ▼ $2.23	$35.62M	1.67	559,574 shs	132,941 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	+3.12%	+4.43%	+17.44%	+20.88%	-47.99%
ADCT ADC Therapeutics	-6.42%	-10.64%	-8.30%	-72.62%	-64.29%
HURA TuHURA Biosciences	-0.23%	+2.84%	-11.43%	-6.87%	-15.89%
NNVC NanoViricides	-1.94%	+2.70%	+12.59%	+16.92%	-9.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.46	Hold	$16.30	146.97% Upside
ADCT ADC Therapeutics	2.33	Hold	$6.25	495.24% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	314.75% Upside
NNVC NanoViricides	3.00	Buy	$6.00	294.74% Upside

Current Analyst Ratings Breakdown

Latest NNVC, AARD, ADCT, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	NNVC NanoViricides	Noble Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
7/6/2026	NNVC NanoViricides	Noble Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/8/2026	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/4/2026	ADCT ADC Therapeutics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$5.00
6/4/2026	ADCT ADC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/4/2026	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$6.00 ➝ $2.00
5/27/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
ADCT ADC Therapeutics	$81.36M	1.64	N/A	N/A	($1.50) per share	-0.70
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-61.71%	-56.29%	N/A
ADCT ADC Therapeutics	-$142.62M	-$1.05	N/A	N/A	N/A	-173.02%	N/A	-44.70%	8/11/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.61	N/A	N/A	N/A	N/A	-156.12%	-105.38%	8/13/2026 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.43	N/A	N/A	N/A	N/A	-87.90%	-78.69%	N/A

Latest NNVC, AARD, ADCT, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	ADCT ADC Therapeutics	-$0.19	N/A	N/A	N/A	$18.89 million	N/A
5/15/2026	Q1 2026	HURA TuHURA Biosciences	-$0.12	-$0.13	-$0.01	-$0.13	N/A	N/A
5/7/2026	Q1 2026	AARD Aardvark Therapeutics	N/A	-$0.99	N/A	-$0.99	N/A	N/A
5/4/2026	Q1 2026	ADCT ADC Therapeutics	-$0.19	-$0.21	-$0.02	-$0.21	$19.99 million	$20.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	8.06	8.06
ADCT ADC Therapeutics	N/A	4.09	4.02
HURA TuHURA Biosciences	N/A	1.15	1.15
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ADCT ADC Therapeutics	41.10%
HURA TuHURA Biosciences	0.62%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
ADCT ADC Therapeutics	5.40%
HURA TuHURA Biosciences	6.06%
NNVC NanoViricides	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
ADCT ADC Therapeutics	310	127.19 million	120.32 million	Optionable
HURA TuHURA Biosciences	N/A	63.68 million	59.82 million	N/A
NNVC NanoViricides	20	22.98 million	14.92 million	Optionable

NNVC, AARD, ADCT, and HURA Headlines

Recent News About These Companies

NanoViricides (NYSE:NNVC) Shares Down 4.3% - What's Next?

July 30 at 3:03 AM | americanbankingnews.com

NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo

July 28, 2026 | finance.yahoo.com

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the ...

July 28, 2026 | finance.yahoo.com

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

July 28, 2026 | accessnewswire.comA

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

July 24, 2026 | accessnewswire.comA

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral ...

July 22, 2026 | finance.yahoo.com

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for ...

July 13, 2026 | oklahoman.comO

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

July 13, 2026 | accessnewswire.comA

Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr ...

July 8, 2026 | usatoday.com

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin ...

July 8, 2026 | finance.yahoo.com

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

July 8, 2026 | accessnewswire.comA

NNVC stock in the limelight after this analyst sees a 350% upside potential – everything to know about its experimental drug for Ebola

July 6, 2026 | msn.com

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

July 6, 2026 | accessnewswire.comA

NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

June 29, 2026 | finanznachrichten.de

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

June 29, 2026 | accessnewswire.comA

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - The Oklahoman

June 23, 2026 | oklahoman.comO

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

June 22, 2026 | accessnewswire.comA

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR ...

June 16, 2026 | finance.yahoo.com

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in ...

June 15, 2026 | usatoday.com

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

June 15, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, AARD, ADCT, and HURA Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$6.60 +0.20 (+3.13%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$6.60 +0.01 (+0.08%)

As of 07/31/2026 07:34 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

ADC Therapeutics NYSE:ADCT

$1.05 -0.06 (-5.41%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$1.06 +0.01 (+0.95%)

As of 07/31/2026 07:34 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

TuHURA Biosciences NASDAQ:HURA

$2.17 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.12 -0.05 (-2.44%)

As of 07/31/2026 07:54 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

NanoViricides NYSE:NNVC

$1.52 -0.03 (-1.94%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.56 +0.04 (+2.37%)

As of 07/31/2026 07:34 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NNVC, AARD, ADCT, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NNVC, AARD, ADCT, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NNVC, AARD, ADCT, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, AARD, ADCT, and HURA Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

ADC Therapeutics NYSE:ADCT

TuHURA Biosciences NASDAQ:HURA

NanoViricides NYSE:NNVC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NNVC, AARD, ADCT, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NNVC, AARD, ADCT, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NNVC, AARD, ADCT, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, AARD, ADCT, and HURA Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

ADC Therapeutics NYSE:ADCT

TuHURA Biosciences NASDAQ:HURA

NanoViricides NYSE:NNVC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools